Swiss drug major Novartis has named Jonathan Symonds deputy chief financial officer and CFO designate under Raymund Breu, who will retire in 2010. Mr Symonds joins the firm from Goldman Sachs and was previously CFO of AstraZeneca, before leaving the Anglo-Swedish company in 2007 after losing out on the chief executive role in 2005.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze